Targeting ADAR1, combined with cisplatin treatment, has shown to amplify the anti‐tumour effects in a patient‐derived xenograft (PDX) model of iCCA with early postoperative recurrence. This evidence concerns the gene ADAR and infantile convulsions and choreoathetosis.